Unicycive Therapeutics (UNCY) Long-Term Deferred Tax (2020 - 2023)
Unicycive Therapeutics' (UNCY) quarterly Long-Term Deferred Tax came in at $6.0 million in Q4 2023, up 43.79% YoY from $4.2 million in Q4 2022, and up 43.79% on a QoQ basis from $4.2 million in Q4 2022.
Unicycive Therapeutics (UNCY) Long-Term Deferred Tax (2020 - 2023) Analysis & Trends
Unicycive Therapeutics (UNCY) has 4 years of Long-Term Deferred Tax data on file, last reported at $6.0 million in Q4 2023.
- Quarterly Long-Term Deferred Tax rose 43.79% year-over-year to $6.0 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $6.0 million (up 43.79% YoY) and the FY2023 annual result came in at $6.0 million, up 43.79% from the prior year.
- Long-Term Deferred Tax climbed to $6.0 million in Q4 2023, from $4.2 million in the prior quarter.
- In the past five years, Long-Term Deferred Tax ranged from a high of $6.0 million in Q4 2023 to a low of $1.1 million in Q4 2020.
- A 4-year average of $3.4 million and a median of $3.2 million in 2021 frame the typical range for Long-Term Deferred Tax.
- Annual changes were most pronounced in 2021 — Long-Term Deferred Tax surged 110.54% — and 2023, when it surged 43.79%.
- Tracing UNCY's Long-Term Deferred Tax over 4 years: stood at $1.1 million in 2020, then surged by 110.54% to $2.3 million in 2021, then jumped by 84.14% to $4.2 million in 2022, then surged by 43.79% to $6.0 million in 2023.
- The last three Long-Term Deferred Tax figures came in at $6.0 million (Q4 2023), $4.2 million (Q4 2022), and $2.3 million (Q4 2021), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Unicycive Therapeutics | 151.01 Mn | 151.01 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 5.98 Mn |
| Dec 31, 2022 | 4.16 Mn |
| Dec 31, 2021 | 2.26 Mn |
| Dec 31, 2020 | 1.07 Mn |